Prognostic impact of a tumor-infiltrating lymphocyte subtype in triple negative cancer of the breast.
Adult
Aged
Aged, 80 and over
Breast
/ cytology
CD4-Positive T-Lymphocytes
/ immunology
CD8-Positive T-Lymphocytes
/ immunology
Carcinoma
/ immunology
Disease-Free Survival
Female
Forkhead Transcription Factors
/ metabolism
Humans
Lymphocytes, Tumor-Infiltrating
/ immunology
Mastectomy
Middle Aged
Neoplasm Recurrence, Local
/ epidemiology
Prognosis
Triple Negative Breast Neoplasms
/ immunology
Breast
CD4
CD8
FOXP3
Triple negative cancer
Journal
Breast cancer (Tokyo, Japan)
ISSN: 1880-4233
Titre abrégé: Breast Cancer
Pays: Japan
ID NLM: 100888201
Informations de publication
Date de publication:
Sep 2020
Sep 2020
Historique:
received:
06
01
2020
accepted:
20
03
2020
pubmed:
31
3
2020
medline:
30
3
2021
entrez:
31
3
2020
Statut:
ppublish
Résumé
Tumor-infiltrating lymphocytes (TILs) have recently been reported as an important factor in the tumor microenvironment and influence the growth and progression of cancer. However, the relationship between immune cell subpopulations, such as CD4+, CD8+, and FOXP3+, in breast cancer, especially in triple negative carcinoma (TNC), remains unclear. The subjects were 107 patients with TNC that were surgically resected at Dokkyo Medical University Hospital between 2006 and 2018. The expression of CD4+, CD8+, and FOXP3+ was evaluated in TILs and expressed as the numbers of positive cells. Univariate analysis revealed that the TILs were not prognostically significant. In multivariate analyses, increased infiltration of intratumoral (i) CD4+ TILs was found to have a good prognosis in relapse-free survival (RFS). In contrast, a high stromal CD8+ TILs level was found to be a favorable prognostic factor in RFS (p = 0.038) and overall survival (OS) (p = 0.046). A low sFOXP3 + TILs level was significantly associated with favorable RFS (p < 0.001) and OS (p = 0.029). The present study demonstrated no difference in TILs and survival in TNC. However, there was a significant correlation in prognosis with levels of iCD4+, sCD8+, and sFOXP3 + TILs in TNC. The difference in TNC clinical outcome may be due to the subtype of the infiltrating TILs.
Sections du résumé
BACKGROUND
BACKGROUND
Tumor-infiltrating lymphocytes (TILs) have recently been reported as an important factor in the tumor microenvironment and influence the growth and progression of cancer. However, the relationship between immune cell subpopulations, such as CD4+, CD8+, and FOXP3+, in breast cancer, especially in triple negative carcinoma (TNC), remains unclear.
METHODS
METHODS
The subjects were 107 patients with TNC that were surgically resected at Dokkyo Medical University Hospital between 2006 and 2018. The expression of CD4+, CD8+, and FOXP3+ was evaluated in TILs and expressed as the numbers of positive cells.
RESULTS
RESULTS
Univariate analysis revealed that the TILs were not prognostically significant. In multivariate analyses, increased infiltration of intratumoral (i) CD4+ TILs was found to have a good prognosis in relapse-free survival (RFS). In contrast, a high stromal CD8+ TILs level was found to be a favorable prognostic factor in RFS (p = 0.038) and overall survival (OS) (p = 0.046). A low sFOXP3 + TILs level was significantly associated with favorable RFS (p < 0.001) and OS (p = 0.029).
CONCLUSIONS
CONCLUSIONS
The present study demonstrated no difference in TILs and survival in TNC. However, there was a significant correlation in prognosis with levels of iCD4+, sCD8+, and sFOXP3 + TILs in TNC. The difference in TNC clinical outcome may be due to the subtype of the infiltrating TILs.
Identifiants
pubmed: 32222891
doi: 10.1007/s12282-020-01084-1
pii: 10.1007/s12282-020-01084-1
pmc: PMC7438376
doi:
Substances chimiques
FOXP3 protein, human
0
Forkhead Transcription Factors
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
880-892Références
Cancer. 2008 Sep 15;113(6):1387-95
pubmed: 18671239
Science. 2006 Sep 29;313(5795):1960-4
pubmed: 17008531
Int J Cancer. 1991 Aug 19;49(1):25-31
pubmed: 1908441
Breast Cancer Res. 2018 Feb 26;20(1):15
pubmed: 29482642
Nat Rev Immunol. 2010 Jul;10(7):490-500
pubmed: 20559327
J Cancer. 2017 Nov 1;8(19):4098-4105
pubmed: 29187886
Am J Transl Res. 2019 Aug 15;11(8):5039-5053
pubmed: 31497220
J Clin Oncol. 2019 Mar 1;37(7):559-569
pubmed: 30650045
Pancreas. 2004 Jan;28(1):e26-31
pubmed: 14707745
Oncology. 2013;85(2):128-36
pubmed: 23948758
Breast Cancer Res. 2007;9(4):212
pubmed: 17705880
Cancer Res. 2001 Jul 1;61(13):5132-6
pubmed: 11431351
Nature. 2003 Feb 20;421(6925):852-6
pubmed: 12594515
Eur J Cancer. 1992;28A(4-5):859-64
pubmed: 1524909
Breast Cancer Res. 2012 Mar 15;14(2):R48
pubmed: 22420471
Hum Pathol. 2006 Sep;37(9):1217-26
pubmed: 16938528
Arch Pathol Lab Med. 2018 Nov;142(11):1364-1382
pubmed: 29846104
J Clin Oncol. 2014 Sep 20;32(27):2959-66
pubmed: 25071121
Science. 2003 Feb 14;299(5609):1057-61
pubmed: 12522256
J Clin Oncol. 2006 Dec 1;24(34):5373-80
pubmed: 17135638
Mod Pathol. 2008 Dec;21(12):1527-32
pubmed: 18820666
Proc Natl Acad Sci U S A. 2003 Jul 8;100(14):8418-23
pubmed: 12829800
Breast Cancer Res Treat. 2014 Dec;148(3):467-76
pubmed: 25361613
Immunol Rev. 2006 Aug;212:8-27
pubmed: 16903903
Breast Cancer Res. 2015 Sep 04;17:124
pubmed: 26341640
Ann Oncol. 2014 Aug;25(8):1536-43
pubmed: 24915873
Anticancer Res. 2009 Jul;29(7):2445-51
pubmed: 19596912
Adv Anat Pathol. 2017 Sep;24(5):235-251
pubmed: 28777142
Proc Natl Acad Sci U S A. 2005 Dec 20;102(51):18538-43
pubmed: 16344461
Int J Oncol. 2006 Jun;28(6):1345-52
pubmed: 16685435
Breast. 2008 Aug;17(4):341-6
pubmed: 18450442
Oncotarget. 2015 Jul 10;6(19):17462-78
pubmed: 25968569
Lancet Oncol. 2018 Jan;19(1):40-50
pubmed: 29233559
Oncol Lett. 2019 Mar;17(3):2647-2656
pubmed: 30867728
Breast Cancer Res Treat. 2011 Nov;130(2):645-55
pubmed: 21717105
J Clin Oncol. 2011 May 20;29(15):1949-55
pubmed: 21483002
Clinics (Sao Paulo). 2006 Jun;61(3):203-8
pubmed: 16832552
Mod Pathol. 2010 Oct;23(10):1357-63
pubmed: 20581807
World J Clin Oncol. 2016 Oct 10;7(5):387-394
pubmed: 27777881